Regulation of the VDJ recombinase during genotoxic stress
基因毒性应激期间 VDJ 重组酶的调节
基本信息
- 批准号:8244037
- 负责人:
- 金额:$ 19.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-25 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntigen ReceptorsAntigensAreaB-LymphocytesBindingBiological AssayCell CycleCell Cycle ArrestCell FractionationCell LineCellsCharacteristicsChemicalsChromatinChromosomal translocationChromosome abnormalityDNADNA DamageDNA Double Strand BreakDNA RepairDNA-PKcsDNA-Protein InteractionDNA-dependent protein kinaseDataDevelopmentEventExposure toFluorescenceFluorescence MicroscopyFoundationsFutureGene ComponentsGenerationsGenesGenetic RecombinationGenomeGenomic InstabilityGenomicsGenotoxic StressGoalsHistone H3Immune systemImmunoglobulinsInvestigationIonizing radiationIonsLeadLymphocyteLymphoidLysineMalignant lymphoid neoplasmMeasuresMediatingMethodsMicroscopyMolecularMonitorMultienzyme ComplexesOncogenesPathway interactionsPatternPeptide Signal SequencesPharmaceutical PreparationsPhasePhosphotransferasesPlantsProbabilityProcessProductionPropertyProteinsRNA InterferenceRadiationRadiation Induced DNA DamageReactionRegulationRiskSiteSystemT-Cell Receptor GenesTestingTimeV(D)J RecombinationVDJ Recombinasesbasecell typeinhibitor/antagonistleukemia/lymphomapreventreceptorrecombinaserepairedresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to determine how cellular localization of the V(D)J recombinase is regulated during genotoxic stress, and if this correlates with reduced DNA cleavage activity. Central to lymphocyte development is the assembly of immunoglobulin and T cell receptor genes from component gene segments. In this process, DNA double strand breaks (DSBs) are generated in an intermediate step by the V(D)J recombinase, which consists of RAG1 and RAG2. This is a particularly risky step, as DSBs are the most genotoxic form of DNA damage. In accordance with this, many lymphomas and leukemias contain characteristic chromosomal translocations between an oncogene and an antigen receptor locus, with breakpoints in the latter locus often attributed to RAG-mediated cleavage. Lymphocytes undergoing genotoxic stress would be at a greater risk of forming such deleterious chromosomal translocations, as more DNA ends would be available to aberrantly join with RAG-produced breaks. Furthermore, DNA damage induces cell cycle arrest in G1. However, as the V(D)J recombinase is stabilized in G1, prolonging this cell cycle phase would be expected to increase the probability of aberrant recombination events. In our preliminary studies using fluorescently tagged RAG proteins, we determined that DNA damage induced by ionizing radiation (IR) prompted a re-localization of the V(D)J recombinase in the cell, which in effect sequestered the enzyme complex from the genome. This was a transient effect, as the pre-DNA damage co-localization properties of the V(D)J recombinase were re- established upon DNA repair. Moreover, the IR-induced redistribution of the V(D)J recombinase was blocked by addition of an inhibitor to DNA damage response (DDR) kinases. Given these results, we hypothesize that during genotoxic stress, the DDR system sequesters the V(D)J recombinase from the genome by disrupting interactions between RAG2 and Histone H3 trimethylated on Lysine 4 (H3K4me3). In this project, we will use fluorescence microscopy combined with assays to monitor cellular protein-protein and protein-DNA interactions. Three specific aims are proposed. First, we will ascertain if spatial regulation of the V(D)J recombinase is a ubiquitous process independent of cell type. Second, we will determine if the interaction between RAG2 and H3K4me3-bound chromatin is disrupted upon IR exposure, and if this occurs independently of RAG1. In addition, the specific DDR factor that mediates this effect will be identified. Third, we will determine if the sequence-specific association with and cleavage activity on RAG recognition sites in the antigen receptor loci are affected by IR-induced DNA damage. This project will provide an important foundation for future studies in understanding mechanisms that regulate the V(D)J recombinase during genotoxic stress. The ability to enhance such a regulatory process may lead to decreased risks of developing lymphoid malignancies following exposure to radiation and other DNA damaging drugs.
PUBLIC HEALTH RELEVANCE: The V(D)J recombinase, consisting of the RAG1 and RAG2 proteins, is essential for development of the adaptive immune system; however, errors in V(D)J recombination can result in genomic instabilities leading to an increased risk of lymphoid malignancies. Preliminary new data indicate the V(D)J recombinase is sequestered from the genome upon exposure to DNA damaging agents in a possible attempt to reduce aberrant recombination reactions. The goal of this study is to determine the mechanistic basis for this effect, and if such a regulatory process leads to reduced V(D)J recombinase activity.
描述(由申请方提供):本项目的目的是确定在遗传毒性强制降解期间V(D)J重组酶的细胞定位如何调节,以及这是否与DNA切割活性降低相关。淋巴细胞发育的中心是从组分基因片段组装免疫球蛋白和T细胞受体基因。在此过程中,DNA双链断裂(DSB)在中间步骤中由V(D)J重组酶产生,其由RAG1和RAG2组成。这是一个特别危险的步骤,因为DSB是最具遗传毒性的DNA损伤形式。根据这一点,许多淋巴瘤和白血病含有癌基因和抗原受体基因座之间的特征性染色体易位,后者基因座中的断点通常归因于RAG介导的切割。经历遗传毒性应激的淋巴细胞形成这种有害染色体易位的风险更大,因为更多的DNA末端可用于与RAG产生的断裂异常连接。此外,DNA损伤诱导细胞周期停滞在G1期。然而,由于V(D)J重组酶稳定在G1期,因此预期延长该细胞周期阶段将增加异常重组事件的概率。在我们使用荧光标记的RAG蛋白的初步研究中,我们确定电离辐射(IR)诱导的DNA损伤促使V(D)J重组酶在细胞中重新定位,这实际上将酶复合物与基因组隔离。这是一种瞬时效应,因为V(D)J重组酶的DNA损伤前共定位特性在DNA修复后重新建立。此外,IR诱导的V(D)J重组酶的再分布被DNA损伤反应(DDR)激酶抑制剂阻断。鉴于这些结果,我们假设在遗传毒性胁迫期间,DDR系统通过破坏RAG2和赖氨酸4上三甲基化的组蛋白H3(H3K4me3)之间的相互作用从基因组中隔离V(D)J重组酶。在本项目中,我们将使用荧光显微镜结合测定来监测细胞蛋白质-蛋白质和蛋白质-DNA相互作用。提出了三个具体目标。首先,我们将确定V(D)J重组酶的空间调控是否是一个独立于细胞类型的普遍存在的过程。其次,我们将确定RAG2和H3K4me3结合的染色质之间的相互作用是否在IR暴露后被破坏,以及这是否独立于RAG1发生。此外,将确定介导这一影响的具体复员方案因素。第三,我们将确定在抗原受体位点的RAG识别位点上的序列特异性关联和切割活性是否受到IR诱导的DNA损伤的影响。该项目将为进一步研究在遗传毒性胁迫下调控V(D)J重组酶的机制提供重要基础。增强这种调节过程的能力可能会降低暴露于辐射和其他DNA损伤药物后发生淋巴恶性肿瘤的风险。
公共卫生相关性:由RAG1和RAG2蛋白组成的V(D)J重组酶对适应性免疫系统的发育至关重要;然而,V(D)J重组中的错误可导致基因组不稳定性,从而导致淋巴恶性肿瘤风险增加。初步的新数据表明,V(D)J重组酶在暴露于DNA损伤剂后从基因组中隔离,可能是为了减少异常重组反应。本研究的目的是确定这种效应的机制基础,以及这种调节过程是否导致V(D)J重组酶活性降低。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karla K Rodgers其他文献
Karla K Rodgers的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karla K Rodgers', 18)}}的其他基金
DNA sequence selectivity in conventional and aberrant V(D)J recombination
常规和异常 V(D)J 重组中的 DNA 序列选择性
- 批准号:
10586433 - 财政年份:2023
- 资助金额:
$ 19.57万 - 项目类别:
Deciphering DNA sequence selectivity in V(D)J recombination
破译 V(D)J 重组中的 DNA 序列选择性
- 批准号:
10307113 - 财政年份:2020
- 资助金额:
$ 19.57万 - 项目类别:
Nuclear export-dependent functions of RAG2 in the DNA damage response system
DNA损伤反应系统中RAG2的核输出依赖性功能
- 批准号:
9387569 - 财政年份:2017
- 资助金额:
$ 19.57万 - 项目类别:
Single cell visualization of the V(D)J recombinase complex
V(D)J 重组酶复合物的单细胞可视化
- 批准号:
9294980 - 财政年份:2016
- 资助金额:
$ 19.57万 - 项目类别:
Regulation of the VDJ recombinase during genotoxic stress
基因毒性应激期间 VDJ 重组酶的调节
- 批准号:
8536667 - 财政年份:2012
- 资助金额:
$ 19.57万 - 项目类别:
Protein-DNA Interactions in V(D)J Recombination
V(D)J 重组中蛋白质-DNA 相互作用
- 批准号:
7003697 - 财政年份:2003
- 资助金额:
$ 19.57万 - 项目类别:
Protein-DNA Interactions in V(D)J Recombination
V(D)J 重组中的蛋白质-DNA 相互作用
- 批准号:
7169240 - 财政年份:2003
- 资助金额:
$ 19.57万 - 项目类别:
Protein-DNA Interactions in V(D)J Recombination
V(D)J 重组中蛋白质-DNA 相互作用
- 批准号:
6598774 - 财政年份:2003
- 资助金额:
$ 19.57万 - 项目类别:
Protein-DNA Interactions in V(D)J Recombination
V(D)J 重组中的蛋白质-DNA 相互作用
- 批准号:
6799213 - 财政年份:2003
- 资助金额:
$ 19.57万 - 项目类别:
Protein-DNA Interactions in V(D)J Recombination
V(D)J 重组中蛋白质-DNA 相互作用
- 批准号:
6840845 - 财政年份:2003
- 资助金额:
$ 19.57万 - 项目类别:
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 19.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 19.57万 - 项目类别:
Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 19.57万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 19.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 19.57万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 19.57万 - 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 19.57万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 19.57万 - 项目类别:
Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 19.57万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
9922602 - 财政年份:2020
- 资助金额:
$ 19.57万 - 项目类别: